July 18th, 2012
FDA Approves Another New Weight Loss Drug
Larry Husten, PHD
The US FDA approved on Tuesday a new weight loss drug that will be called Qsymia, the brand name for the combination of two previously approved drugs, phentermine and extended-release topiramate. The drug is manufactured by Vivus, Inc. In a press release, the FDA said Qsymia had been approved for use in obese adults (BMI of 30 or […]
April 11th, 2011
Phentermine-Topiramate Combination Yields Significant Weight Loss
Larry Husten, PHD
The experimental diet drug combination of phentermine and topiramate demonstrated “robust efficacy” in CONQUER, a large new trial published online in the Lancet. The trial’s results come after a year in which the FDA turned down three investigational diet drugs (including Qnexa, the phentermine-topiramate combination used here) and removed the diet drug sibutramine from the […]
NEJM Journal Watch — Recent Cardiology Articles- Atrial Fibrillation and Stable Coronary Artery Disease — What Is the Optimal Anticoagulation–Antiplatelet Regimen?
- β-Blockers After Myocardial Infarction
- Updated Guideline for Perioperative Cardiovascular Management of Patients Undergoing Noncardiac Surgery
- Strategies and Criteria for the Diagnosis and Management of Myocarditis
- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?